Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00LNW
|
||||
Former ID |
DIB005469
|
||||
Drug Name |
KPT-330
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 2 | [524584] | ||
Company |
Karyopharm therapeutics
|
||||
Structure |
Download2D MOL |
||||
Formula |
C17H11F6N7O
|
||||
Canonical SMILES |
C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)<br />F)C(F)(F)F
|
||||
InChI |
1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-
|
||||
InChIKey |
DEVSOMFAQLZNKR-RJRFIUFISA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Drug Resistance Mutation (DRM) | |||||
DRM | DRM Info | ||||
Target and Pathway | |||||
Target(s) | Exportin-1 | Target Info | Inhibitor | [544432] | |
Pathway Interaction Database | Signaling events mediated by HDAC Class II | ||||
Canonical NF-kappaB pathway | |||||
Integrin-linked kinase signaling | |||||
Signaling events mediated by HDAC Class I | |||||
Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||||
FoxO family signaling | |||||
Sumoylation by RanBP2 regulates transcriptional repression | |||||
Hedgehog signaling events mediated by Gli proteins | |||||
Regulation of nuclear beta catenin signaling and target gene transcription | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.